References:

Arnaldez, F. I., O’Day, S. J., Drake, C. G., Fox, B. A., Fu, B., Urba, W. J., . . . Ascierto, P. A. (2020). The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response. Journal for immunotherapy of cancer, 8 (1), e000930. doi:10.1136/jitc-2020-000930
Bannwarth, B., & Richez, C. (2011). Clinical safety of tocilizumab in rheumatoid arthritis. Expert opinion on drug safety, 10 (1), 123-131.
Campochiaro, C., Della-Torre, E., Cavalli, G., De Luca, G., Ripa, M., Boffini, N., . . . Ruggeri, A. (2020). Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. European journal of internal medicine .
Capra, R., De Rossi, N., Mattioli, F., Romanelli, G., Scarpazza, C., Sormani, M. P., & Cossi, S. (2020). Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia.European journal of internal medicine .
Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S. C., & Di Napoli, R. (2020). Features, evaluation and treatment coronavirus (COVID-19)Statpearls [internet] : StatPearls Publishing.
Chi, Z., Zhao, W., Jia-Wen, L., Hong, Z., & Gui-Qiang, W. (2020). Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.International journal of antimicrobial agents, 55 (5), 105954.
Chugh, T. (2020). Timelines of COVID-19 Vaccines. Current Medicine Research and Practice .
Colaneri, M., Bogliolo, L., Valsecchi, P., Sacchi, P., Zuccaro, V., Brandolino, F., . . . Bruno, R. (2020). Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms, 8 (5), 695.
Elsawah, H. K., Elsokary, M. A., Elrazzaz, M. G., & ElShafey, A. H. (2020). Hydroxychloroquine for treatment of non‐severe COVID‐19 patients; systematic review and meta‐analysis of controlled clinical trials. Journal of Medical Virology .
Fardet, L., Galicier, L., Lambotte, O., Marzac, C., Aumont, C., Chahwan, D., . . . Hejblum, G. (2014). Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome.Arthritis & Rheumatology, 66 (9), 2613-2620.
Guaraldi, G., Meschiari, M., Cozzi-Lepri, A., Milic, J., Tonelli, R., Menozzi, M., . . . Borghi, V. (2020). Tocilizumab in patients with severe COVID-19: a retrospective cohort study. The Lancet Rheumatology .
Hoffmann-La Roche, A. (2020). Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (COVACTA) . Retrieved from https://www.roche.com/dam/jcr:6d8de90d-2e31-43c8-b4e1-0a24a2675015/en/29072020-mr-covacta.pdf
Horby, P., Lim, W. S., Emberson, J., Mafham, M., Bell, J., Linsell, L., . . . Elmahi, E. (2020). Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. medRxiv .
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., . . . Gu, X. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet, 395 (10223), 497-506.
Ip, A., Berry, D. A., Hansen, E., Goy, A. H., Pecora, A. L., Sinclaire, B. A., . . . Berry, N. S. (2020). Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients-An Observational Study. medRxiv .
Jayaweera, M., Perera, H., Gunawardana, B., & Manatunge, J. (2020). Transmission of COVID-19 virus by droplets and aerosols: A critical review on the unresolved dichotomy. Environmental Research , 109819.
Kewan, T., Covut, F., Al–Jaghbeer, M. J., Rose, L., Gopalakrishna, K., & Akbik, B. (2020). Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study. EClinicalMedicine , 100418.
Klopfenstein, T., Zayet, S., Lohse, A., Balblanc, J.-C., Badie, J., Royer, P.-Y., . . . Bozgan, A.-M. (2020). Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients.Médecine et Maladies Infectieuses .
Lan, S.-H., Lai, C.-C., Huang, H.-T., Chang, S.-P., Lu, L.-C., & Hsueh, P.-R. (2020). Tocilizumab for severe COVID-19: a systematic review and meta-analysis. International journal of antimicrobial agents , 106103.
Leverenz, D. L., & Tarrant, T. K. (2020). Is the HScore useful in COVID-19? The lancet, 395 (10236), e83.
Losilla, J.-M., Oliveras, I., Marin-Garcia, J. A., & Vives, J. (2018). Three risk of bias tools lead to opposite conclusions in observational research synthesis. Journal of clinical epidemiology, 101 , 61-72.
Nishimoto, N., & Kishimoto, T. (2008). Humanized antihuman IL-6 receptor antibody, tocilizumab Therapeutic Antibodies (pp. 151-160): Springer.
Roche, H.-L. (2020). A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (COVACTA) . Retrieved from https://www.roche.com/dam/jcr:6d8de90d-2e31-43c8-b4e1-0a24a2675015/en/29072020-mr-covacta.pdf
Rojas-Marte, G., Khalid, M., Mukhtar, O., Hashmi, A. T., Waheed, M. A., Ehrlich, S., . . . Malyshev, Y. (2020). Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case–controlled study.QJM: An International Journal of Medicine, 113 (8), 546-550.
Rossi, B., Nguyen, L. S., Zimmermann, P., Boucenna, F., Baucher, L., Dubret, L., . . . Salem, J.-E. (2020). Effect of tocilizumab in hospitalized patients with severe pneumonia COVID-19: a cohort study.medRxiv .
Rossotti, R., Travi, G., Ughi, N., Corradin, M., Baiguera, C., Fumagalli, R., . . . Bellone, A. (2020). Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis.Journal of infection .
Siracusano, G., Pastori, C., & Lopalco, L. (2020). Humoral Immune Responses in COVID-19 Patients: A Window on the State of the Art.Frontiers in Immunology, 11 .
Somers, E. C., Eschenauer, G. A., Troost, J. P., Golob, J. L., Gandhi, T. N., Wang, L., . . . Dillman, N. O. (2020). Tocilizumab for treatment of mechanically ventilated patients with COVID-19. medRxiv .
Somers, E. C., Eschenauer, G. A., Troost, J. P., Golob, J. L., Gandhi, T. N., Wang, L., . . . Pogue, J. M. (2020). Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clinical Infectious Diseases . doi:10.1093/cid/ciaa954
Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., . . . Boutron, I. (2016). ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.bmj, 355 .
Ulhaq, Z. S., & Soraya, G. V. (2020). Interleukin-6 as a potential biomarker of COVID-19 progression. Médecine et Maladies Infectieuses .
Wang, W., Ye, L., Ye, L., Li, B., Gao, B., Zeng, Y., . . . Wu, Z. (2007). Up-regulation of IL-6 and TNF-α induced by SARS-coronavirus spike protein in murine macrophages via NF-κB pathway. Virus research, 128 (1-2), 1-8.
Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., . . . Li, X. (2020). Effective treatment of severe COVID-19 patients with tocilizumab.Proceedings of the National Academy of Sciences, 117 (20), 10970-10975.
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., . . . Zhu, L. (2020). Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine, 8 (4), 420-422.
Ye, Q., Wang, B., & Mao, J. (2020). The pathogenesis and treatment of theCytokine Storm’in COVID-19. Journal of infection, 80 (6), 607-613.
Yuki, K., Fujiogi, M., & Koutsogiannaki, S. (2020). COVID-19 pathophysiology: A review. Clinical immunology , 108427.